Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanadelumab for prevention of acute attacks in non-histaminergic angioedema with normal C1-INH and acquired angioedema due to C1-INH deficiency
2019-001703-20Phase 3Unknown
- Sponsor
- Dyax Corp.
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-histaminergic angioedema with normal C1-inhibitor and acquired C1 esterase inhibitor deficiency (AAE) comparing Lanadelumab with Placebo (2 arms). Primary endpoint: Number of investigator-confirmed angioedema attacks during the treatment period. Status: unknown.
02
Drugs
lanadelumab
03
Conditions
non-histaminergic angioedema with normal C1-inhibitoracquired C1 esterase inhibitor deficiency (AAE)
Beyond the preview
Go deeper on 2019-001703-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001703-20.